What retatrutide is

Retatrutide (also written LY3437943) is described in the literature as an agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon receptors ^[1]. It sits in the same broad research area as other incretin-based compounds pepmg tracks, but with an added glucagon-receptor action.

The phase 2 trial authors noted at the outset that retatrutide's dose-response relationships for side effects, safety, and efficacy in obesity were not known — i.e. these were open research questions the trial set out to measure, not settled facts ^[1].

What the human research has measured

The main published human study is a phase 2, double-blind, randomized, placebo-controlled trial in 338 adults with obesity (or overweight plus a weight-related condition), run over 48 weeks with a primary endpoint of percentage change in body weight at 24 weeks ^[1].

The trial reported least-squares mean body-weight changes at 48 weeks of roughly −8.7% to −24.2% across the retatrutide groups versus about −2.1% in the placebo group; the most common adverse events reported were gastrointestinal, described as dose-related and mostly mild to moderate ^[1]. These are trial measurements in a research setting, not evidence of real-world benefit or safety.

A separate phase 2a trial examined retatrutide in metabolic dysfunction-associated steatotic liver disease ^[2], and a systematic review and meta-analysis has since pooled retatrutide randomized-trial data on weight and metabolic markers ^[3]. Together these are early-phase human studies — informative, but far short of the multi-trial phase 3 base that established, approved medicines rest on.

What the trials report on safety and adverse events

The phase 2 trial measured safety as well as weight, and reported that the most common adverse events were gastrointestinal: dose-related, mostly mild to moderate, and partially mitigated by using a lower starting dose ^[1]. It also reported dose-dependent increases in heart rate that peaked around 24 weeks and then declined ^[1]. The trial's authors had stated at the outset that retatrutide's dose-response relationships for side effects and safety were not known, so these are first measurements from a single early-phase study, not a settled profile ^[1].

The systematic review and meta-analysis pooled the available randomized data and reported an increase in non-severe gastrointestinal and hypersensitivity adverse events with retatrutide versus placebo, while noting that phase 3 randomized trials are awaited to characterize longer-term efficacy and safety ^[3]. As of this review there is no phase 3 program or regulatory approval reflected in the retatrutide literature, so the long-term human safety picture is not established.

These are measured rates within small, early-phase research populations, not a safety guarantee and not a prediction for any individual. Retatrutide is sold by third parties for laboratory and research use only. This is not medical advice; consult a qualified professional and read the studies directly.

How strong is the evidence

Human randomized data exists, which is why this review is characterized as moderate rather than preclinical — but it is early-phase (phase 2), the sample sizes are modest, and there is no phase 3 program or regulatory approval reflected in this literature ^[1][2][3].

Nothing here says retatrutide works, is safe, or is appropriate for human use. It is sold by third parties for laboratory and research use only. Read the studies themselves and consult a qualified professional — this page is a map to the evidence, not a recommendation.